Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2025)
Historic Return on Capital Employed for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 0.14%.
- Janux Therapeutics' Return on Capital Employed fell 200.0% to 0.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.14% for FY2024, which is 600.0% up from last year.
- As of Q3 2025, Janux Therapeutics' Return on Capital Employed stood at 0.14%, which was down 200.0% from 0.14% recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Return on Capital Employed registered a high of 0.06% during Q3 2021, and its lowest value of 0.23% during Q2 2023.
- Its 5-year average for Return on Capital Employed is 0.15%, with a median of 0.14% in 2025.
- In the last 5 years, Janux Therapeutics' Return on Capital Employed crashed by -1200bps in 2022 and then surged by 1400bps in 2024.
- Quarter analysis of 5 years shows Janux Therapeutics' Return on Capital Employed stood at 0.09% in 2021, then crashed by -115bps to 0.19% in 2022, then decreased by -4bps to 0.2% in 2023, then skyrocketed by 42bps to 0.11% in 2024, then decreased by -26bps to 0.14% in 2025.
- Its Return on Capital Employed was 0.14% in Q3 2025, compared to 0.14% in Q2 2025 and 0.11% in Q1 2025.